Investigating future pharmacists' understanding of vaccines and myths surrounding vaccination
Abstract
Objective: The United Kingdom has lost its measles, mumps and rubella free status due to a decline in vaccination uptake. There are several beliefs such as safety concern and media influence that discourage people from having vaccinations. To identify gaps in knowledge of vaccination within 3rd year pharmacy students, and to observe whether they can spot myths about vaccines, in particular the measles, mumps and rubella vaccine. Methods: A questionnaire-based approach was used after gaining ethical approval which included a range of open and closed questions. Results: None of the participants could identify the six common myths reported by the World Health Organisation and 40% failed to accurately identify the type of vaccine of the measles, mumps and rubella vaccine. There were clear gaps in knowledge on vaccines in participants particularly from black, Asian and minority ethnic group participants compared to white students. Educating participants about the myths could have positive future implications on their scientific knowledge when they work as pharmacists. Conclusion: Many students did not accurately identify the myths surrounding vaccines and were provided informative leaflets to enhance their scientific knowledge. The gaps in knowledge identified, demonstrates that further teaching sessions should be implemented to cover the grey areas, allowing them to appropriately recommend vaccinations in the future.Citation
Zahid, S., Morrissey, H. and Ball, P. (2020) Investigating future pharmacists' understanding of vaccines and myths surrounding vaccination, International Journal of Current Pharmaceutical Research, 12 (5), pp. 95-98. DOI: 10.22159/ijcpr.2020v12i5.39778.Publisher
Innovare Academic SciencesJournal
International Journal of Current Pharmaceutical ResearchType
Journal articleLanguage
enDescription
© 2020 The Authors. Published by Innovare Academic Sciences. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.22159/ijcpr.2020v12i5.39778ISSN
0975-7066ae974a485f413a2113503eed53cd6c53
10.22159/ijcpr.2020v12i5.39778
Scopus Count
Collections
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell responseRamasamy, Karthik; Sadler, Ross; Jeans, Sally; Weeden, Paul; Varghese, Sherin; Turner, Alison; Larham, Jemma; Gray, Nathanael; Carty, Oluremi; Barrett, Joe; et al. (Wiley, 2022-01-22)Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Using a prospective study of myeloma patients in UK Rudy Study cohort, we assessed humoral and Interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration. We report data from 214 adults with myeloma (n=204) or smouldering myeloma (n=10) who provided blood samples at least 3 weeks after second vaccine dose. Positive Anti-Spike antibody levels (> 50 IU/ml) were detected in 189/203 (92.7%), positive IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a negative IGRA and negative Anti-Spike protein antibody response. 95/158 (60.1%) patients produced positive results for both anti-Spike protein serology and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/ anti-BCMA therapy and Pfizer-BioNTech (PB) vaccination. Further work is required to understand the clinical significance of divergent cellular response to vaccination.
-
Ultra scale-down approaches to study the centrifugal harvest for viral vaccine productionMelinek, Beatrice J; Dessoy, Sandrine; Wright, Bernice; Bracewell, Dan G; Mukhopadhyay, Tarit K (Wiley, 2018-01-08)Large scale continuous cell‐line cultures promise greater reproducibility and efficacy for the production of influenza vaccines, and adenovirus for gene therapy. This paper seeks to use an existing validated ultra scale‐down tool, which is designed to mimic the commercial scale process environment using only milliliters of material, to provide some initial insight into the performance of the harvest step for these processes. The performance of industrial scale centrifugation and subsequent downstream process units is significantly affected by shear. The properties of these cells, in particular their shear sensitivity, may be changed considerably by production of a viral product, but literature on this is limited to date. In addition, the scale‐down tool used here has not previously been applied to the clarification of virus production processes. The results indicate that virus infected cells do not actually show any increase in sensitivity to shear, and may indeed become less shear sensitive, in a similar manner to that previously observed in old or dead cell cultures. Clarification may be most significantly dependent on the virus release mechanism, with the budding influenza virus producing a much greater decrease in clarification than the lytic, non‐enveloped adenovirus. A good match was also demonstrated to the industrial scale performance in terms of clarification, protein release, and impurity profile.
-
The uptake study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancySethi, Sonika; Kumar, Aditi; Mandal, Anandadeep; Shaikh, Mohammed; Hall, Claire A; Kirk, Jeremy MW; Moss, Paul; Brookes, Matthew J; Basu, Supratik (BMJ, 2021-06-15)Objective: A key challenge towards a successful COVID-19 vaccine uptake is vaccine hesitancy. We examine and provide novel insights on the key drivers and barriers towards COVID-19 vaccine uptake. Design: This study involved an anonymous cross-sectional online survey circulated across the UK in September 2020. The survey was designed to include several sections to collect demographic data and responses on: i) extent of agreement regarding various statements about COVID-19 and vaccinations; ii) previous vaccination habits (e.g. if they had previously declined vaccination); and iii) interest in participation in vaccine trials. Multi-nominal logistic models examined demographic factors that may impact vaccine uptake. We used principle component analysis and text mining to explore perception related to vaccine uptake. Setting: The survey was circulated through various media, including: posts on social media networks (Facebook, Twitter, LinkedIn and Instagram), national radio, news articles, Clinical Research Network (CRN) website and newsletter, and through 150 West Midlands general practices via a text messaging service. Participants: There was a total of 4884 respondents of which 9.44% were BAME (Black Asian Minority Ethnic) group. The majority were females (n=3416, 69·9%) and of White ethnicity (n=4127, 84·5%). Results: Regarding respondents, overall 3873 (79·3%) were interested in taking approved COVID-19 vaccines while 677 (13·9%) were unsure, and 334 (6·8%) would not take a vaccine. Participants aged over 70 years (Odds Ratio (OR)=4·63) and the BAME community (OR=5·48) were more likely to take an approved vaccine. Smokers (OR=0·45) and respondents with no known illness (OR=0·70) were less likely to accept approved vaccines. The study identified 16 key reasons for not accepting approved vaccines, the most common (60%) being the possibility of the COVID-19 vaccine having side effects. Conclusions: This study provides an insight into focusing on specific populations to reduce vaccine hesitancy. This proves crucial in managing the COVID-19 pandemic.